Product Code: RP-ID-10086107 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10086107
Market Overview:
Global Hematology Analyzer Market: Analysis By Type (3-part, 5-part, 6-part), By Modality (POC, Standalone), By End User, By Region, By Country (2018 Edition): Opportunities and Forecast 2022-2030
" The Hematology Analyzer market is divided by product (instruments (3-part blood analyzers, 5-part blood analyzers, blood analyzers for instant detection and others), reagents and services), end users (hospitals, clinical laboratories, research institutions, And others) and geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The report provides the value (in millions of U.S. dollars) for the aforementioned market segments.
The compound annual growth rate of the blood analyzer market during the forecast period 2022-2030 is expected to be 8%. More and more attention has been paid to the hematology parameters used to evaluate COVID-19 around the world. Research institutions and many hospitals have conducted multiple studies. Start using blood analyzers to assess and monitor COVID-19 patients without spreading the virus.
In order to effectively detect a large number of people infected with COVID-19, some studies in China suggest adding white blood cells (WBC) and C-reactive protein (CRP) to laboratory tests for early detection of infection. On March 18, 2020, Sight announced that the Israeli government-operated Sheba Tel Hashomer Hospital is using its OLO, which is the first bedside blood count device to perform CBC testing to monitor and treat COVID-19 patients to reduce risk.
The comments published in the Journal of Physiological Review indicate that high levels of enzymes involved in preventing thrombosis may be a common risk factor for COVID-19. In addition, given the rapid spread of the pandemic and the lack of literature so far, the correct treatment and management of coronavirus infection (COVID-19) for patients affected by hematological diseases may be a challenge. The market includes an increase in the burden of blood diseases, an increase in technological progress, and an increase in the adoption rate of automated hematology instruments. Blood diseases have become a global health problem.
The causes vary and are associated with high mortality rates. Blood diseases, such as anemia, blood cancer, bleeding conditions, and blood infections, affect millions of people of all age groups every year. According to data from the Commonwealth of Australia in 2018, more than 330,000 affected babies are born each year (83% of sickle cell disease and 17% of thalassemia), approximately 7% of pregnant women are carriers of hemoglobin disease, and more than 1% worldwide Of couples are at risk. According to data from the World Federation of Hemophilia, the global prevalence of male hemophilia is about 17 per 100,000 men in 2019. Except for the same source, the number of people diagnosed with hemophilia increased from 78,629 in 1999 to 210,454 in 2018. Similarly, according to the Global Hemophilia Care 2019 report, there are more than 1,125,000 men worldwide with inherited bleeding disorders, of which 418,000 are the severe version of the disease, mostly undiagnosed.
Early diagnosis and treatment is the best way to protect the quality of life of patients with blood cell diseases. Therefore, the increase in the burden of blood diseases is likely to drive the market in the future. However, the high cost of blood analyzers and the strict and time-consuming regulatory policies associated with them have limited the overall growth of the market.
REPORT SCOPE :
According to the scope of this report, a blood analyzer is a device for testing blood samples, used in the medical field for white blood cell counts, complete blood counts, reticulocyte analysis and coagulation tests. .The blood analyzer market is by product (instruments (3-part blood analyzers, 5-part blood analyzers, blood analyzers for instant detection and others), reagents and services), end users (hospitals, clinical laboratories, and research institutions) And other). ) And geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The report provides the value (in millions of U.S. dollars) for the aforementioned market segments.
MAIN MARKET TRENDS:
As COVID-19 cases and cross-border transportation congestion and suppression are found to have an impact on the system supply chain, the three-part hematology analyzer is the instrument segment that is expected to have the largest market share. Initially, due to lack of manpower to influence the growth of this segment, many manufacturers have stopped production. However, increasing attention to hematology parameters for COVID-19 assessment has increased the demand for hematology analyzers. In the context of the COVID-19 pandemic, the three-piece hematology analyzer proved to be cost-effective because of the large number of samples that need to be analyzed. In addition, after the COVID-19 pandemic, demand may also increase. In addition, the three-part differential cell counter uses Coulter's principle to determine the size and volume of cells. The sample is smooth and dissolved in the electrolyte solution in the container, which also contains a smaller container.
The 3-part hematology analyzer system is ideal for small hospitals, clinics, and doctors office laboratories to perform medium-complexity tests. There is increasing interest in the 5-piece hematology analyzer, but the 3-piece hematology analyzer is more cost-effective for routine hematology testing. In addition, with the advancement of technology and the availability and affordability of these instruments around the world, the market is expected to grow significantly.
In March 2019, Transasia Bio-Medicals Ltd launched a differentiated hematology analyzer. Fully automated 3-part (3PD) components, reagents and quality controls are manufactured in India by Erba Lachema, a wholly-owned European subsidiary of Transasia. Later, in September 2019, Transasia Bio-Medicals Ltd. Announced that more than 1,000 Erba blood analyzer series have been successfully sold in India. In April 2019, Prestige Diagnostics launched the new Hematron 3 PLUS hematology analyzer globally. It is a 3-part differential hematology analyzer that can perform 18 parameters using 3 histograms. In addition, the clinical laboratory as the end user is the center for hematology testing.
They usually have high-quality equipment and the results obtained from them are accurate. Laboratory automation increases the cost of equipment in this area, but the analyzers in these laboratories are not often replaced. The clinical testing laboratory conducts various tests on whole blood, serum, urine, cerebrospinal fluid and other body fluids. In addition, convenient and accurate results are the two main reasons driving the market segment growth during the forecast period.
NORTH AMERICA IS EXPECTED TO DETERMINE THE MARKET STUDY:
The United States is one of the countries most severely affected by COVID in the world. Due to the COVID-19 outbreak, due to delays in diagnosis, shortage of medicines and other reasons, the market is expected to face a slight setback. However, the COVID-19 outbreak is expected to affect the market because patients with blood diseases such as hemophilia need to take additional precautions to minimize the risk of contracting COVID-19, as this population is more susceptible to infectious diseases. The blood analyzer market in North America is growing steadily. This can be attributed to the increase in the burden of blood diseases and the increase in the adoption of blood analyzers in the diagnostic industry. For example, anemia is a common disease that affects more than 3 million Americans, especially women of childbearing age. According to the report of the World Federation of Hemophilia in 2018, about 17,757 people in the United States were diagnosed with hemophilia in 2018. . In addition, according to NHF (National Health Federation) data, the number of hemophilia patients in the United States increased to approximately 20,000 in 2019. In addition, according to the Leukemia and Lymphoma Association, one person in the United States is diagnosed with blood cancer every three minutes. In 2019, approximately 176,200 people in the United States were diagnosed with leukemia, lymphoma or myeloma.
There are many market participants in the country and they continue to focus on the development and launch of new products. In December 2019, the Beckman Coulter subsidiary of Danaher Corporation launched the new DxH 690T blood analyzer. Designed to help laboratories optimize workflow and maximize uptime. Similarly, in April 2019, Ortho Clinical Diagnostics collaborated with Diazyme Laboratories Inc. Launched the D-dimer test, which is Ortho’s MicroTip Cooperative Test (MPA) program in the United States for the latest product for coagulation testing. In addition, in the United States, there are many partners who can help doctors and scientists from all over the world who are working hard to overcome these blood diseases. In addition, many centers in the state are international leaders in the diagnosis and treatment of blood diseases, and cooperate on many research projects to improve the diagnosis and treatment of blood diseases. These factors have driven the demand for blood analyzers in North America.
COMPETITIVE LANDSCAPE :
Due to the existence of various market participants, the market under study is a fragmented market. Some market participants include Abbott Laboratories, Beckman Coulter, Inc. (Danaher Corporation), Bio-Rad Laboratories, Boule Diagnostics AB, F. Hoffmann-La Roche Ltd, Hobira Ltd, Nihon Kohden Corporation, Mindray Medical International Co., Ltd. (Shenzhen Mindray Bio-Medical Electronics Co., Ltd.), Siemens Healthineers and Sysmex Corporation
MAIN PARTICIPANT:
Abbott LaboratoriesHORIBA Ltd Siemens HealthineersSysmex Corporation Danaher Corporation
Latest Developments In May 2020, Montpellier University Hospital (CHU de Montpellier) collaborated with HORIBA Medical to classify patients using Microsemi CRP and Pentra MS CRP hematology analyzers for more severe respiratory evolution related to positive reactions Predictive biomarker development project. Test for COVID-19 infection. In February 2021, Beckman Coulter was established. Announced the launch of the desktop hematology analyzer DxH 560 AL. "
Sysmex, Nihon Kohden, Boule Diagnostics, HORIBA, Beckman Coulters, Abbott Laboratories, Siemens, EKF Diagnostics, Bio-Rad, Drew Scientific, BioSystems.
Related Reports
Proof of Quality & Reliability
